BCL2-interacting protein (Harakiri) (HRK)

Harakiri (HRK), also known as BCL2-interacting protein or DP5, is a potent pro-apoptotic member of the BCL-2 protein family that belongs to the BH3-only sensitizer subgroup. It plays a critical role in the intrinsic apoptotic pathway by selectively interacting with and neutralizing the anti-apoptotic proteins BCL-2 and BCL-XL, but notably lacks affinity for MCL-1 or BCL-W (UniProt P56273; PMID: 9144161). This interaction triggers mitochondrial outer membrane permeabilization (MOMP), leading to the release of pro-apoptotic factors like cytochrome c and the eventual activation of the caspase cascade. HRK expression is tightly regulated and typically induced by cellular stress signals such as growth factor withdrawal, DNA damage, or amyloid-beta exposure in neurons (PMID: 11956108). In clinical oncology, HRK is recognized as a putative tumor suppressor, often silenced through epigenetic mechanisms like promoter hypermethylation in various malignancies, including gastric, colorectal, and prostate cancers (PMID: 15632204). Conversely, its pathological upregulation is implicated in neuronal loss during neurodegenerative conditions and following ischemic stroke. While direct pharmacological agonists of HRK are not currently in clinical use, the protein's mechanism serves as the biological template for 'BH3 mimetics' like Venetoclax and Navitoclax, which are designed to replicate the inhibitory action of proteins like HRK on anti-apoptotic BCL-2 family members. Furthermore, HRK expression and methylation status are being investigated as potential biomarkers for predicting patient sensitivity to chemotherapeutic agents and HDAC inhibitors (PMID: 11059345).

Other names

HRKDP5HarakiriDeath protein 5Bcl-2-interacting protein

HRK induces apoptosis by selectively binding to and antagonizing anti-apoptotic BCL-2 family members, specifically BCL-2 and BCL-XL, via its BH3 domain, thereby promoting mitochondrial outer membrane permeabilization (MOMP) and subsequent cytochrome c release.